Research & Literature

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

Gnant M, Pfeiler G, Dubsky PC, et al.

Lancet (London, England) 2015; (386(9992)):433-43.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, et al.

The New England journal of medicine 2015; (373(21)):2005-14 doi:10.1056/NEJMoa1510764.

American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.

Runowicz CD, Leach CR, Henry NL, et al.

CA: a cancer journal for clinicians 2016; (66(1)):43-73 doi:10.3322/caac.21319.

Interobserver Variability of Ki-67 Measurement in Breast Cancer.

Chung YR, Jang MH, Park SY, et al.

Journal of pathology and translational medicine 2016; (50(2)):129-37 doi:10.4132/jptm.2015.12.24.

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.

Burstein HJ, Lacchetti C, Anderson H, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(14)):1689-701 doi:10.1200/JCO.2015.65.9573.

Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?

Markopoulos C, van de Velde C, Zarca D, et al.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2017; (43(5)):909-920 doi:10.1016/j.ejso.2016.08.012.

A perspective on anti-EGFR therapies targeting triple-negative breast cancer.

Nakai K, Hung MC, Yamaguchi H

American journal of cancer research 2016; (6(8)):1609-23.

Women's experiences and preferences regarding breast imaging after completing breast cancer treatment.

Brandzel S, Rosenberg DE, Johnson D, et al.

Patient preference and adherence 2017; (11()):199-204 doi:10.2147/PPA.S122244.

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

Masuda N, Lee SJ, Ohtani S, et al.

The New England journal of medicine 2017; (376(22)):2147-2159 doi:10.1056/NEJMoa1612645.

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.

Dhesy-Thind S, Fletcher GG, Blanchette PS, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(18)):2062-2081 doi:10.1200/JCO.2016.70.7257.

Prognostic and predictive biomarkers in breast cancer: Past, present and future.

Nicolini A, Ferrari P, Duffy MJ

Seminars in cancer biology 2018; (52(Pt 1)):56-73 doi:10.1016/j.semcancer.2017.08.010.

Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer.

Weiss A, Chavez-MacGregor M, Lichtensztajn DY, et al.

JAMA oncology 2018; (4(2)):203-209 doi:10.1001/jamaoncol.2017.4298.

The new TNM-based staging of breast cancer.

Cserni G, Chmielik E, Cserni B, Tot T

Virchows Archiv : an international journal of pathology 2018; (472(5)):697-703 doi:10.1007/s00428-018-2301-9.

Fear of Cancer Recurrence: A Practical Guide for Clinicians.

Butow P, Sharpe L, Thewes B, et al.

Oncology (Williston Park, N.Y.) 2018; (32(1)):32-8.

Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia.

Grossmann M, Ramchand SK, Milat F, et al.

Clinical endocrinology 2018; (89(3)):280-296 doi:10.1111/cen.13735.

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

Wolff AC, Hammond MEH, Allison KH, et al.

Archives of pathology & laboratory medicine 2018; (142(11)):1364-1382 doi:10.5858/arpa.2018-0902-SA.

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, et al.

The New England journal of medicine 2018; (379(2)):111-121 doi:10.1056/NEJMoa1804710.

Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer.

Thill M, Schmidt M

Therapeutic advances in medical oncology 2018; (10()):1758835918793326 doi:10.1177/1758835918793326.

New and Important Changes in the TNM Staging System for Breast Cancer.

Hortobagyi GN, Edge SB, Giuliano A

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2018; (38()):457-467 doi:10.1200/EDBK_201313.

Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm.

Boyle F, Beith J, Burslem K, et al.

Asia-Pacific journal of clinical oncology 2018; (14 Suppl 4()):3-11 doi:10.1111/ajco.13064.

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.

Burstein HJ, Lacchetti C, Anderson H, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(5)):423-438 doi:10.1200/JCO.18.01160.

The effects of adjuvant endocrine therapy on bone health in women with breast cancer.

Ramchand SK, Cheung YM, Yeo B, Grossmann M

The Journal of endocrinology 2019; (241(3)):R111-R124.

Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

André F, Ciruelos E, Rubovszky G, et al.

The New England journal of medicine 2019; (380(20)):1929-1940 doi:10.1056/NEJMoa1813904.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.

Andre F, Ismaila N, Henry NL, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(22)):1956-1964 doi:10.1200/JCO.19.00945.

Acceptance and commitment therapy for breast cancer survivors with fear of cancer recurrence: A 3-arm pilot randomized controlled trial.

Johns SA, Stutz PV, Talib TL, et al.

Cancer 2020; (126(1)):211-218 doi:10.1002/cncr.32518.

Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.

Allison KH, Hammond MEH, Dowsett M, et al.

Archives of pathology & laboratory medicine 2020; (144(5)):545-563 doi:10.5858/arpa.2019-0904-SA.

Mindfulness-Based Cognitive Therapy for Psychological Distress, Fear of Cancer Recurrence, Fatigue, Spiritual Well-Being, and Quality of Life in Patients With Breast Cancer-A Randomized Controlled Trial.

Park S, Sato Y, Takita Y, et al.

Journal of pain and symptom management 2020; (60(2)):381-389 doi:10.1016/j.jpainsymman.2020.02.017.

Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy.

Rugo HS, Ettl J, Hurvitz SA, et al.

JNCI cancer spectrum 2020; (4(1)):pkz085 doi:10.1093/jncics/pkz085.

Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy.

Zhao Y, Schaafsma E, Cheng C

Cancer medicine 2020; (9(17)):6281-6295 doi:10.1002/cam4.3284.

Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS.

Tsourdi E, Zillikens MC, Meier C, et al.

The Journal of clinical endocrinology and metabolism 2020; doi:10.1210/clinem/dgaa756.

Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment.

Raschi E, Fusaroli M, Ardizzoni A, et al.

Breast cancer research and treatment 2021; (186(1)):219-227 doi:10.1007/s10549-020-06001-w.

The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population.

Beyerlin K, Jimenez R, Zangardi M, et al.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2021; (27(8)):1883-1890 doi:10.1177/1078155220971751.

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

Cortes J, Cescon DW, Rugo HS, et al.

Lancet (London, England) 2020; (396(10265)):1817-1828 doi:10.1016/S0140-6736(20)32531-9.

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.

Korde LA, Somerfield MR, Carey LA, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(13)):1485-1505 doi:10.1200/JCO.20.03399.

Breast Cancer Staging: Updates in the AJCC Cancer Staging Manual, 8th Edition, and Current Challenges for Radiologists, From the AJR Special Series on Cancer Staging.

Teichgraeber DC, Guirguis MS, Whitman GJ

AJR. American journal of roentgenology 2021; (217(2)):278-290 doi:10.2214/AJR.20.25223.

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.

Rugo HS, Lerebours F, Ciruelos E, et al.

The Lancet. Oncology 2021; (22(4)):489-498 doi:10.1016/S1470-2045(21)00034-6.

Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials.

Schreiber AR, Kagihara JA, Weiss JA, et al.

Frontiers in oncology 2021; (11()):640690 doi:10.3389/fonc.2021.640690.

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.

Bardia A, Hurvitz SA, Tolaney SM, et al.

The New England journal of medicine 2021; (384(16)):1529-1541 doi:10.1056/NEJMoa2028485.

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

Tutt ANJ, Garber JE, Kaufman B, et al.

The New England journal of medicine 2021; (384(25)):2394-2405 doi:10.1056/NEJMoa2105215.

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.

Burstein HJ, Somerfield MR, Barton DL, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(35)):3959-3977 doi:10.1200/JCO.21.01392.

Correlation of manual semi-quantitative and automated quantitative Ki-67 proliferative index with OncotypeDXTM recurrence score in invasive breast carcinoma.

Finkelman BS, Meindl A, LaBoy C, et al.

Breast disease 2022; (41(1)):55-65 doi:10.3233/BD-201011.

The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis.

Paakkola NM, Karakatsanis A, Mauri D, et al.

ESMO open 2021; (6(6)):100289 doi:10.1016/j.esmoop.2021.100289.

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.

Kalinsky K, Barlow WE, Gralow JR, et al.

The New England journal of medicine 2021; (385(25)):2336-2347 doi:10.1056/NEJMoa2108873.

Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.

Swain SM, Nishino M, Lancaster LH, et al.

Cancer treatment reviews 2022; (106()):102378 doi:10.1016/j.ctrv.2022.102378.

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.

Andre F, Ismaila N, Allison KH, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(16)):1816-1837 doi:10.1200/JCO.22.00069.

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

Bidard FC, Kaklamani VG, Neven P, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(28)):3246-3256 doi:10.1200/JCO.22.00338.

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.

Modi S, Jacot W, Yamashita T, et al.

The New England journal of medicine 2022; (387(1)):9-20 doi:10.1056/NEJMoa2203690.

The effect of psychological interventions on fear of cancer recurrence in breast cancer survivors: A systematic review and meta-analysis.

Lyu MM, Siah RC, Lam ASL, Cheng KKF

Journal of advanced nursing 2022; (78(10)):3069-3082 doi:10.1111/jan.15321.

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.

Cortes J, Rugo HS, Cescon DW, et al.

The New England journal of medicine 2022; (387(3)):217-226 doi:10.1056/NEJMoa2202809.

Triple negative breast cancer: Pitfalls and progress.

Zagami P, Carey LA

NPJ breast cancer 2022; (8(1)):95 doi:10.1038/s41523-022-00468-0.

Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?

Bonadio RC, Tarantino P, Testa L, et al.

Cancer treatment reviews 2022; (110()):102459 doi:10.1016/j.ctrv.2022.102459.

Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.

Rugo HS, Bardia A, Marmé F, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(29)):3365-3376 doi:10.1200/JCO.22.01002.

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.

Rugo HS, Tolaney SM, Loirat D, et al.

NPJ breast cancer 2022; (8(1)):98 doi:10.1038/s41523-022-00467-1.

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.

Geyer CE, Garber JE, Gelber RD, et al.

Annals of oncology : official journal of the European Society for Medical Oncology 2022; (33(12)):1250-1268 doi:10.1016/j.annonc.2022.09.159.

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.

Johnston SRD, Toi M, O'Shaughnessy J, et al.

The Lancet. Oncology 2023; (24(1)):77-90 doi:10.1016/S1470-2045(22)00694-5.

The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations.

Finkelman BS, Zhang H, Hicks DG, Turner BM

Cancers 2023; (15(3)) doi:10.3390/cancers15030808.

Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer.

Huppert LA, Gumusay O, Idossa D, Rugo HS

CA: a cancer journal for clinicians 2023; (73(5)):480-515 doi:10.3322/caac.21777.

HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast.

Bardia A, Viale G

Targeted oncology 2023; (18(3)):313-319 doi:10.1007/s11523-023-00964-8.

Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer: Overcoming Challenges in Genetic Testing and Clinical Considerations When Using Talazoparib.

Brugioni E, Cathcart-Rake E, Metsker J, et al.

Clinical breast cancer 2023; (23(5)):469-477 doi:10.1016/j.clbc.2023.04.006.

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.

Wolff AC, Somerfield MR, Dowsett M, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(22)):3867-3872 doi:10.1200/JCO.22.02864.

Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel.

Chiu JWY, Lee SC, Ho JC, et al.

Drug safety 2023; (46(10)):927-949 doi:10.1007/s40264-023-01328-x.

Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer.

Mohamed A, Kruse M, Tran J

Expert review of anticancer therapy 2023; (23(10)):1071-1084 doi:10.1080/14737140.2023.2262764.

Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.

Bedrosian I, Somerfield MR, Achatz MI, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024; (42(5)):584-604 doi:10.1200/JCO.23.02225.

Ribociclib plus Endocrine Therapy in Early Breast Cancer.

Slamon D, Lipatov O, Nowecki Z, et al.

The New England journal of medicine 2024; (390(12)):1080-1091 doi:10.1056/NEJMoa2305488.

Gastrointestinal Toxicity of Antibody Drug Conjugates (ADCs) in Metastatic Breast Cancer: A Pooled Analysis.

Pedersini R, Buffoni M, Petrelli F, et al.

Clinical breast cancer 2024; (24(5)):411-420 doi:10.1016/j.clbc.2024.04.003.

Practical Guidance on Abemaciclib in Combination with Adjuvant Endocrine Therapy for Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative High-Risk Early Breast Cancer.

O'Keefe K, Desai NV, Tan AR

Breast cancer (Dove Medical Press) 2024; (16()):517-527 doi:10.2147/BCTT.S271441.

Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability - Real-World Data from German Breast Centers.

Schäffler H, Jakob D, Huesmann S, et al.

Geburtshilfe und Frauenheilkunde 2024; (84(9)):855-865 doi:10.1055/a-2375-5194.

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.

Bardia A, Jhaveri K, Im SA, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(3)):285-296 doi:10.1200/JCO.24.00920.

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.

Bardia A, Hu X, Dent R, et al.

The New England journal of medicine 2024; (391(22)):2110-2122 doi:10.1056/NEJMoa2407086.

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.

Schmid P, Cortes J, Dent R, et al.

The New England journal of medicine 2024; (391(21)):1981-1991 doi:10.1056/NEJMoa2409932.

Surveillance-Associated Anxiety After Curative-Intent Cancer Surgery: A Systematic Review.

Khatri R, Quinn PL, Wells-Di Gregorio S, et al.

Annals of surgical oncology 2025; (32(1)):47-62 doi:10.1245/s10434-024-16287-5.

Gene expression profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review.

Cooper K, Nalbant G, Essat M, et al.

Breast cancer research and treatment 2025; (210(2)):229-247 doi:10.1007/s10549-024-07596-0.

Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study.

Provenzano L, Dieci MV, Curigliano G, et al.

Annals of oncology : official journal of the European Society for Medical Oncology 2025; (36(7)):762-774 doi:10.1016/j.annonc.2025.03.023.

Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study.

Andrade MO, Gutierres IG, Tavares MC, et al.

Breast (Edinburgh, Scotland) 2025; (83()):104473 doi:10.1016/j.breast.2025.104473.

HER2-Low Breast Cancer-Current Knowledge and Future Directions.

Shaaban AM, Kaur T, Provenzano E

Medicina (Kaunas, Lithuania) 2025; (61(4)) doi:10.3390/medicina61040644.

Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.

Hu X, Zhang Q, Sun T, et al.

Nature communications 2025; (16(1)):4324 doi:10.1038/s41467-025-59210-6.

Adverse effect of trastuzumab deruxtecan in solid tumours: A systematic review and meta-analysis.

Pathak N, Di Iorio M, Gimenez DM, et al.

Critical reviews in oncology/hematology 2025; (213()):104787 doi:10.1016/j.critrevonc.2025.104787.

Treatment and prognosis of patients with hormone receptor-low positive (1%-10%) breast cancer: a retrospective propensity score-matched analysis.

Luo Y, Saibaidula Y, Sun Y, et al.

Breast cancer (Tokyo, Japan) 2025; (32(5)):1023-1034 doi:10.1007/s12282-025-01730-6.

Analytical Comparison of Commonly Used Laboratory-Developed Tests for the Assessment of Ki-67 in Breast Carcinoma With a Food and Drug Administration-Approved Benchmark.

Badve S, White JS, Sapunar F, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2025; (38(10)):100813 doi:10.1016/j.modpat.2025.100813.

Hepatotoxicity across CDK 4/6 inhibitors: a Narrative Review.

Wong WHF, Vasiliu S, McFarlane T

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2025; (33(7)):588 doi:10.1007/s00520-025-09625-0.

Sacituzumab govitecan in HER2-negative breast cancer: redefining treatment paradigms.

Khadela A, Morakhia KR, Shah NH, et al.

Journal of drug targeting 2025; (33(10)):1743-1756 doi:10.1080/1061186X.2025.2525372.

Population Pharmacokinetics and Exposure-Response Analyses for Capivasertib in Combination With Fulvestrant in Patients With Breast Cancer.

Fernandez Teruel C, Cullberg M, González-García I, et al.

Clinical and translational science 2025; (18(7)):e70286 doi:10.1111/cts.70286.

US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Receptor 2-Ultralow Breast Cancer.

Dilawari A, Zhang H, Shah M, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(26)):2942-2951 doi:10.1200/JCO-25-00812.

Questions and answers on PARP inhibitor use in somatic BRCA-mutated breast cancers.

Tung N, Hollis RL, Viale G, et al.

Journal of the National Cancer Institute 2026; (118(2)):205-213 doi:10.1093/jnci/djaf205.

Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.

Modi S, Jacot W, Iwata H, et al.

Nature medicine 2025; (31(12)):4205-4213 doi:10.1038/s41591-025-03981-4.

New Perspectives in the Management of Triple-Negative Breast Cancer.

Bartsch R, Bago-Horvath Z, Egle D, et al.

Breast care (Basel, Switzerland) 2026; (21(2)):152-165 doi:10.1159/000547988.

Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: a systematic review and network meta-analysis.

Buonaiuto R, Fordellone M, Caltavituro A, et al.

EClinicalMedicine 2025; (89()):103535 doi:10.1016/j.eclinm.2025.103535.

International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer: Focus on HER2-Low and Ultralow Categories.

Rakha EA, Tan PH, Van Bockstal MR, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2026; (39(1)):100925 doi:10.1016/j.modpat.2025.100925.

Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer.

Zattarin E, Marra A, Palazzo A, et al.

NPJ breast cancer 2025; (11(1)):145 doi:10.1038/s41523-025-00859-z.

Risk of QTc prolongation, and major cardiovascular adverse events associated with CDK4/6 inhibitors in hormone receptor-positive HER2-negative breast cancer - A systematic review and meta-analysis.

Hoo YY, Sia WW, Jaya-Prakason S, et al.

Cancer treatment reviews 2026; (142()):103069 doi:10.1016/j.ctrv.2025.103069.

Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer.

Singareeka Raghavendra A, Damodaran S, Barcenas CH, et al.

CA: a cancer journal for clinicians 2026; (76(1)):e70055 doi:10.3322/caac.70055.

Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.

Kuemmel S, Fasching PA, Schmid P, et al.

Annals of surgical oncology 2026; (33(6)):5550-5557 doi:10.1245/s10434-026-19121-2.

Ki-67 as a treatment decision modifier in breast cancer.

Dy A, Lennerz JK

The oncologist 2026; (31(7)) doi:10.1093/oncolo/oyag183.

Navigating Treatment Decisions in Early-Stage Hormone Receptor-Positive Breast Cancer.

Amir E, Kristoff T, Blaha C, et al.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2026; (46(3)):e520488 doi:10.1200/EDBK-26-520488.

Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

Caswell-Jin JL, Somerfield MR, Khan MA, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026; 101200JCO2602034 doi:10.1200/JCO-26-02034.